The brain data science company

Empowering the future of Alzheimer’s Clinical Trials with a unique blend of digital patient recruitment and AI-driven profiling.

Breaking barriers in Alzheimer's Reasearch

Recruiting participants for clinical trials remains one of the major obstacles to advancing treatments for neurodegenerative diseases.

Qairnel offers a transformative solution by combining DocMemo, an innovative digital clinic, with AI-powered profiling to accelerate recruitment and improve trial success rates.

Our solution

Early diagnosis and AI expertise meets precision profiling.

DocMemo: Screening Patients Through Their Healthcare Journey

DocMemo seamlessly integrates into the patient’s healthcare pathway, transforming traditional screening methods:

Early intervention: Online memory assessments identify cognitive concerns at an early stage.
Actionable insights: Personalized recommendations guide patients through their care journey, with trial participation offered as an option.
Rich, real-world data: High-quality data collected during routine assessments ensures precise profiling for clinical trials.

Since its launch, DocMemo has engaged 9,000 patients, collecting 350,000 data points (Q4 2024).

Learn more on our BtoC platform: DocMemo.

Boosting Data Value with AI-Driven Profiling

Transforming trial success through advanced analytics.

Predict trial eligibility: Reduce costly screening failures with precise AI models.
Identify fast progressors: Optimize cohorts to enhance trial success rates.
Digital twins: Simulate patient responses to design smarter, more efficient trials.

Our AI technology is validated on 5,000+ patients across 4 continents, patented, and published in top-tier journals.

Why partner with Qairnel ?

From patient identification to trial profiling and predictive modeling, Qairnel streamlines every stage of the recruitment process to accelerate timelines and deliver better outcomes.

Profile and match precisely

Use AI-powered profiling to reduce screening failures and select fast progressors, optimizing trial outcomes.

Accelerate timelines

Deliver pre-qualified patients directly to trial sites, streamlining recruitment and reducing delays.

Identify patients early

Leverage DocMemo and innovative digital tools to evaluate cognitive concerns and identify early-stage patients.

Our expertise

At Qairnel, we merge decades of neuroscience research with cutting-edge AI and data science to advance clinical trials for neurodegenerative diseases:

Scientific foundation: 10+ years of research inherited from the Paris Brain Institute.
Tailored innovations: Proprietary cognitive tests and AI models designed for Alzheimer’s and Parkinson’s.
Global recognition: Published in top-tier journals and validated in international open challenges.

Our commitment to precision and rigor ensures better trial outcomes and sets a new standard for Alzheimer’s research.

About us

Qairnel is a spin-off of the Paris Brain Institute and the first digital CRO specializing in Alzheimer’s and neurodegenerative diseases.

We combine scientific expertise, proprietary data, and advanced technology to transform patient recruitment and trial design.